Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01569035
Other study ID # wuoh
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 2009
Est. completion date July 2011

Study information

Verified date January 2021
Source Woman's Health University Hospital, Egypt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study examines using oral anti coagulant warfarin in the management of unexplained oligohydramnios improve the perinatal outcome with little or no complications to the mother or the neonates.


Description:

A randomized controlled study with 200 pregnant women with idiopathic oligohydramnios between 28 and 32 weeks. Women were randomized to receive 3 mg warfarin daily (Warfarin group) or placebo (Placebo group). Outcomes included amniotic fluid index (AFI), duration of pregnancy and perinatal outcomes including Apgar score, Neonatal intensive care admission (NICU). Patients were eligible for inclusion if they were 28t to 32 weeks of pregnancy and age 18-35 years and diagnosed to have idiopathic oligohydramnios excluded by medical history and detailed u/s examination,the cut off AFI was less than 5cm. A written informed consent was taken. Gestational age was determined on the basis of the last menstrual period, confirmed by an ultrasound scan conducted between 6 and 14 weeks of gestation The clinical work-up included a history taken prior to enrollment, examination, obstetric ultrasound evaluation, and biophysical profile taken after 32 weeks of pregnancy Exclusion criteria were chronichypertension, anaemia ,cardiac diseases ,or history of premature rupture of membrane or structural malformations. Sterile speculum examination was done to exclude rupture of membrane. Detailed level 2D ultrasonography to determine the possible etiology and to exclude the multiple pregnancy and fetal death. All fetuses were alive with fetal weight were prior treatment and each follow up visits. Doppler ultrasound for uterine, umbilical and middle cerebral arteries, and fetal ascending aorta was done using resistant index (RI), pulsetilty index (PI) and systolic/diastolic (S/D) ratio before and in each follow up visits. Laboratory tests were obtained included complete blood picture, liver function test, immunological tests to exclude antiphospholipid antibodies was done. After these all patients with unknown major cause were classified as idiopathic oligohydramnios and the treatment started to them. The patients were randomly allocated to 2 treatment groups using computer-generated numbers in sealed envelopes. Treatment was started immediately after the test result was known, and continued until 36 completed weeks of pregnancy or active onset of labor. The patients were randomized to receive either a daily dose of 3 mg warfarin oral tablet or a daily placebo sachet The placebo sachets were especially manufactured to look identical to warfarin tablets. The tablets were placed in sacs and then stored in envelopes numbered from 1 to 200 The envelopes were numbered and randomized according to computer-generated randomization tables to ensure an equal number of patients in each arm. Throughout the trial, access to the randomization code was available only to the pharmacist who manufactured the placebo and packed the envelopes and was not available to any of the treating physicians or patients Treatment protocol: One tablet of 3 mg of warfarin was provided daily to each patient in Warfarin group and placebo to Placebo group. After starting the treatment; weekly follow up of the patient for four weeks till 36 weeks and 2 weeks thereafter. Each follow up visit the following were done; assessment of the amniotic fluid, biophysical profile including non stress test (NST), Doppler U/S of fetal ascending aorta, uterine, middle cerebral and umbilical arteries. Laboratory measurement of prothrombine time and concentration and INR are checked daily until in the therapeutic range for 2 consecutive days, then twice a week for 1-2 weeks, then weekly until stable. Change in a patient's condition, e.g. liver disease, intercurrent illness, and new drug started necessitates more frequent testing. Patients should be advised to report any bruising or bleeding immediately, as advised, avoid aspirin but use paracetamol for pain ,avoid contact sports and activities carrying a risk of head injury. During labor or cesarean section visual inspection of blood loss and 48 hours follow up for the occurrence of hematomas and neonatal follow up for any bleeding problems. Discontinuation of treatment was done if after two weeks of treatment no changes of the amniotic fluid, manifestation of fetal distress appeared or the patient completed 36 weeks of gestation. Assessment of outcome measures The primary outcome was improvement of the amniotic fluid and improving the biophysical profile. The secondary outcome is prolongation of pregnancy till suitable time of fetal maturity. The baseline characteristics of the study participants were analyzed including amniotic fluid index, Doppler indices changes of the fetal and maternal vessles, mode of the delivery and the rate of continuation of pregnancy. Finally, the maternal and neonatal complications and the cost of the treatment were calculated. Statistical analysis: . Data collected and analyzed by computer program SPSS version 17 Chicago -USA - Data expressed as mean ± S.D, number and percentage - Using Paried t.test to determine significance for numeric variable - Using Pearson´s correlation to determine significance between variables N.S= P > 0.05 No significance - = P < 0.05 Significant.


Recruitment information / eligibility

Status Terminated
Enrollment 200
Est. completion date July 2011
Est. primary completion date July 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Patients were eligible for inclusion if they were 28th to 32nd weeks of pregnancy and - age 18-35 years and - diagnosed to have idiopathic oligohydramnios excluded by medical history and - detailed u/s examination, - the cut off AFI was less than 5cm Exclusion Criteria: - Exclusion criteria were chronic hypertension, - anaemia, - cardiac diseases,or - history of premature rupture of membrane or - structural malformations.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
warfarin
3 mg warfarin oral tablet for 2 to 3 weeks

Locations

Country Name City State
Egypt Women Health Hospital Assiut

Sponsors (1)

Lead Sponsor Collaborator
Woman's Health University Hospital, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome was improvement of the amniotic fluid and improving the biophysical profile The primary outcome was improvement of the amniotic fluid and improving the biophysical profile 2 to 3 three weeks
Secondary The secondary outcome is prolongation of pregnancy till suitable time of fetal maturity The baseline characteristics of the study participants were analyzed including amniotic fluid index, Doppler indices changes of the fetal and maternal vessles, mode of the delivery and the rate of continuation of pregnancy. Finally, the maternal and neonatalcomplications and the cost of the treatment were calculated.intention to treat analysis is done. 4 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03277417 - Does Amniotic Fluid Index Affect the Fetal Cardiac Performance? N/A
Recruiting NCT00787163 - Amnioinfusion Initiative Phase 3
Completed NCT05059093 - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Not yet recruiting NCT05043753 - "Fetal gRowth AbnorMality dEtection Trial" N/A
Recruiting NCT02997345 - PPROM Registry (Preterm Premature Rupture of Membranes)
Completed NCT03935607 - The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index
Completed NCT02581774 - Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term Phase 4
Completed NCT01140971 - Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor N/A
Recruiting NCT04684680 - The Role of Zamzam Water in Idiopathic Oligohydramnios N/A
Not yet recruiting NCT03815968 - Low Sodium Diet in Oligohydramnios Assigned for Conservative Management N/A
Enrolling by invitation NCT04451109 - Dilapan-S®: A Multicenter US E-registry
Recruiting NCT02901340 - Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios N/A
Terminated NCT01682928 - Hydrotherapy for the Reversal of Oligohydramnios N/A
Not yet recruiting NCT05474326 - Effect of Intermittent Pneumatic Compression Device of Lower Limbs in Oligohydramnios N/A
Completed NCT05332015 - The Effect of Oral Hypotonic Hydration in Isolated Oligohydramnios N/A